Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 12/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26539472 | 0.91 | SCN5A (0.42) | SCN5ASCN1ASCN2ACYP1A2KDM1A | |
| SCHEMBL20204001 | 0.86 | CYP1A2 (0.50) | SCN5ASCN1ASCN2ACYP1A2CACNA2D1 | |
| SCHEMBL12909222 | 0.81 | SCN5A (0.55) | SCN5ASCN1ASCN2ACYP1A2 | |
| SCHEMBL20203973 | 0.81 | SCN5A (0.52) | SCN5ASCN1ASCN2ACYP1A2CACNA2D1 | |
| SCHEMBL26539471 | 0.78 | CYP1A2 (0.45) | SCN5ASCN1ASCN2ACYP1A2CACNA2D1 | |
| SCHEMBL20203983 | 0.74 | SCN5A (0.57) | SCN5ASCN1ASCN2ACYP1A2CACNA2D1 | |
| SCHEMBL936490 | 0.71 | SCN5A (0.53) | SCN5ASCN1ASCN2ACYP1A2 | |
| SCHEMBL23571497 | 0.71 | SCN5A (0.64) | SCN5ASCN1ASCN2ACYP1A2 | |
| SCHEMBL937183 | 0.71 | SCN5A (0.58) | SCN5ASCN1ASCN2ACYP1A2 | |
| SCHEMBL937091 | 0.70 | CYP1A2 (0.72) | SCN5ASCN1ASCN2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885SCN1A 1/4885SCN2A 4/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885SCN1A 1/4885SCN2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.